Measurement of antiretroviral drugs in the lungs of HIV-infected patients.

TitleMeasurement of antiretroviral drugs in the lungs of HIV-infected patients.
Publication TypeJournal Article
Year of Publication2010
AuthorsTwigg HL, Schnizlein-Bick CT, Weiden M, Valentine F, Wheat J, Day RB, Rominger H, Zheng L, Collman RG, Coombs RW, R Bucy P, Rezk NL, Kashuba ADm
JournalHIV Ther
Volume4
Issue2
Pagination247-251
Date Published2010 Mar 1
ISSN1758-4310
Abstract

AIMS: Prior studies have shown that HAART is associated with decreased HIV viral load in the lungs. The correlation between antiretroviral exposure in bronchoalveolar lavage (BAL) fluid and virologic response was evaluated in patients starting HAART and enrolled in The AIDS Clinical Trial Group Protocol 723. MATERIALS #ENTITYSTARTX00026; METHODS: A total of 24 subjects underwent blood and BAL sampling prior to starting HAART, and after 4 and 24 weeks of HAART. Drug concentrations and HIV RNA were measured in paired plasma and BAL samples. RESULTS: Antiretroviral drugs, including efavirenz, were detectable in BAL fluid of HIV-infected subjects beginning HAART. Efavirenz was also associated with a higher likelihood of clearing HIV RNA from the lungs. CONCLUSION: These results suggest the excellent pulmonary virologic response to antiretroviral therapy may, in part, be due to penetration of antiretroviral drugs into the alveolar compartment.

DOI10.2217/hiv.10.5
Alternate JournalHIV Ther
PubMed ID20436781
PubMed Central IDPMC2861507
Grant ListM01 RR000750 / RR / NCRR NIH HHS / United States
M01 RR000750-320749 / RR / NCRR NIH HHS / United States
P30 AI050410 / AI / NIAID NIH HHS / United States
P30 AI050410-08 / AI / NIAID NIH HHS / United States
R01 HL059834-05 / HL / NHLBI NIH HHS / United States